Tribulus terrestris

Phase 3Small molecule

FFederal University of Minas Gerais

Tribulus terrestris is one of 48 small molecule programs targeting Efficacy and Safety. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Efficacy and SafetyRecruiting

Efficacy and SafetyPhase 3

Recruiting

Competition

Competitive Landscape

242 competitors in Efficacy and Safety

#DrugCompanyPhaseTrials

Savaysa

Daiichi Sankyo

Phase 3

3 2

Fludara

Sanofi

Phase 3

1 3

Tuoyi

SSun Yat-sen University

Phase 3

4 4

Gilotrif

Boehringer Ingelheim

Phase 3

3 5

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

3 6

Busulfex

Akero Therapeutics

Phase 3

3 7

UPLIZNA

HHorizon Therapeutics Ireland DAC

Phase 3

1 8

Oxycontin

PPurdue Pharma LP

Phase 3

1 9

Giapreza

LLa Jolla Pharmaceutical Company

Phase 3

1 10

Alka-Seltzer

AAbbott

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Menopausal Women1 trial

Effects of Tribulus Terrestris on Sexual Function in Post-menopausal Women

Completed·FFaculdade de Ciências Médicas da Santa Casa de São Paulo·Phase 4·NCT01407445·60 enrolled

Postmenopausal Women1 trial

Effects of Tribulus Terrestris in Postmenopausal Women With Hypoactive Sexual Desire Disorder

Completed·FFederal University of Minas Gerais·Phase 4·NCT01975649·44 enrolled

Women1 trial

Effects of Tribulus Terrestris in Women With Hypoactive Sexual Desire Disorder

Completed·FFederal University of Minas Gerais·Phase 4·NCT01971099·44 enrolled

Efficacy and Safety1 trial

Efficacy and Safety Study of Products Based on Tribulus Terrestris, L. in Men With Oligospermia

Recruiting·HHerbarium Laboratorio Botanico Ltda·Phase 4·NCT06260007·204 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Tribulus terrestris. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Tribulus terrestris compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Tribulus terrestris. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Federal University of Minas Gerais company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 3[1]
Company: FFederal University of Minas Gerais

Tribulus terrestris

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Menopausal Women1 trial

Postmenopausal Women1 trial

Women1 trial

Efficacy and Safety1 trial

References

Drug Info

Quick Facts

Related News